/PGNY
PGNY Stock - Progyny, Inc.
Healthcare|Medical - Healthcare Information ServicesNASDAQ
$26.63+1.80%
+$0.47 (+1.80%) • Dec 19
74
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.90
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).72
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.81
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.8%upside
Target: $29.51
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PGNY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$26.36 – $26.90
TARGET (TP)$29.50
STOP LOSS$24.50
RISK/REWARD1:1.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.97
52W High$27.51
52W Low$14.12
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.17B | $1.09B | $786.91M | $500.62M | $344.86M |
| Gross Profit | $253.36M | $238.80M | $167.32M | $112.14M | $70.06M |
| Gross Margin | 21.7% | 21.9% | 21.3% | 22.4% | 20.3% |
| Operating Income | $67.45M | $62.18M | $23.34M | $32.34M | $8.35M |
| Net Income | $54.34M | $62.04M | $30.36M | $65.77M | $46.46M |
| Net Margin | 4.7% | 5.7% | 3.9% | 13.1% | 13.5% |
| EPS | $0.59 | $0.65 | $0.33 | $0.74 | $0.54 |
Company Overview
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
60%
Hold / Neutral
4
40%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
6 Bullish4 Neutral/Bearish
Price Targets
$37
Average Target
↑ 38.5% Upside
Now
$17
Low
$37
Average
$56
High
Based on 16 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Overweight | $29 |
| November 12th 2025 | KeyBanc Capital Markets | Upgrade | Overweight | $30 |
| July 8th 2025 | Leerink Partners | Upgrade | Outperform | $28 |
| December 2nd 2024 | JP Morgan | Downgrade | Neutral | $17 |
| November 13th 2024 | Truist | Downgrade | Hold | $19← $26 |
| September 19th 2024 | JMP Securities | Downgrade | Market Perform | - |
| August 7th 2024 | Canaccord Genuity | Downgrade | Hold | $24← $37 |
| August 7th 2024 | BTIG Research | Downgrade | Neutral | - |
| August 7th 2024 | Leerink Partners | Downgrade | Market Perform | $25← $31 |
| July 16th 2024 | JMP Securities | Initiation | Mkt Outperform | $36 |
| May 10th 2024 | KeyBanc Capital Markets | Downgrade | Sector Weight | - |
| February 26th 2024 | Leerink Partners | Initiation | Outperform | $49 |
| January 3rd 2024 | Barclays | Initiation | Overweight | $48 |
| September 27th 2023 | Canaccord Genuity | Initiation | Buy | $46 |
| May 22nd 2023 | BTIG Research | Initiation | Buy | $50 |
Earnings History & Surprises
PGNYBeat Rate
100%
Last 18 quarters
Avg Surprise
+124.5%
EPS vs Estimate
Beats / Misses
18/0
Last 12 quarters
Latest EPS
$0.45
Q4 2025
EPS Surprise History
Q1 24
+190.9%
$0.32vs$0.11
Q2 24
+178.6%
$0.39vs$0.14
Q3 24
+19.4%
$0.43vs$0.36
Q4 24
+8.1%
$0.40vs$0.37
Q1 25
+13.5%
$0.42vs$0.37
Q2 25
+6.7%
$0.48vs$0.45
Q3 25
+9.1%
$0.48vs$0.44
Q4 25
+15.4%
$0.45vs$0.39
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.38 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.39 | $0.45 | +15.4% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $0.44 | $0.48 | +9.1% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.45 | $0.48 | +6.7% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $0.37 | $0.42 | +13.5% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $0.37 | $0.40 | +8.1% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.36 | $0.43 | +19.4% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $0.14 | $0.39 | +178.6% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $0.11 | $0.32 | +190.9% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $0.12 | $0.16 | +33.3% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $0.10 | $0.15 | +50.0% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $0.07 | $0.18 | +157.1% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $0.01 | $0.03 | +157.1% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $0.05 | $0.13 | +160.0% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $0.05 | $0.09 | +80.0% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $0.01 | $0.05 | +525.0% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $0.04 | $0.15 | +316.7% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $0.06 | $0.17 | +183.3% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $0.08 | $0.19 | +137.5% | ✓ BEAT |
Latest News
Barclays Initiates Coverage On Progyny with Overweight Rating, Announces Price Target of $29
📈 PositiveBenzinga•Dec 9, 2025, 04:13 PM•Also:
Politico Reported The White House To Propose A Two-year Extension Of Obamacare Subsidies With New Limits On Eligibility
➖ NeutralBenzinga•Nov 24, 2025, 11:16 AM•Also: , ,
Progyny shares are trading higher after Canaccord Genuity maintained a Hold rating on the stock and raised its price target from $23 to $26.
📈 PositiveBenzinga•Nov 17, 2025, 05:47 PM•Also:
Progyny CEO buys $1.93M in company stock
📈 PositiveSeeking Alpha•Nov 17, 2025, 03:48 PM
Canaccord Genuity Maintains Hold on Progyny, Raises Price Target to $26
➖ NeutralBenzinga•Nov 17, 2025, 01:55 PM•Also:
Keybanc Upgrades Progyny to Overweight, Announces $30 Price Target
📈 PositiveBenzinga•Nov 12, 2025, 12:43 PM
JP Morgan Maintains Neutral on Progyny, Raises Price Target to $26
➖ NeutralBenzinga•Nov 11, 2025, 03:59 PM
Progyny Raises FY2025 GAAP EPS Guidance from $0.58-$0.65 to $0.65-$0.68 vs $0.62 Est
📈 PositiveBenzinga•Nov 6, 2025, 09:16 PM
Progyny Raises FY2025 Adj EPS Guidance from $1.70-$1.78 to $1.79-$1.82 vs $0.62 Est; Raises FY2025 Sales Guidance from $1.235B-$1.270B to $1.263B-$1.278B vs $1.259B Est
📈 PositiveBenzinga•Nov 6, 2025, 09:16 PM
Progyny Sees Q4 GAAP EPS $0.14-$0.17 vs $0.14 Est
📈 PositiveBenzinga•Nov 6, 2025, 09:15 PM
Progyny Sees Q4 2025 Adj EPS $0.37-$0.40 vs $0.14 Est; Sees Sales $292.700M-$307.700M vs $302.589M Est
📈 PositiveBenzinga•Nov 6, 2025, 09:14 PM
Progyny's Board Authorizes Up to $200M In Share Repurchase Program
📈 PositiveBenzinga•Nov 6, 2025, 09:13 PM
Progyny Q3 Adj. EPS $0.45 Beats $0.29 Estimate, Sales $313.346M Beat $299.836M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:02 PM
Progyny seesaws amid confusion over impact from Trump's IVF initiative
📉 NegativeSeeking Alpha•Oct 17, 2025, 05:11 PM
Shares of fertility stocks are trading lower amid possible profit taking after a report yesterday suggested that the White House is set to announce a proposal that would make IVF more accessible.
➖ NeutralBenzinga•Oct 17, 2025, 02:19 PM•Also: , ,
Deputy Director Of The White House Domestic Policy Council Says New Fertility Benefit Option For Employers To Offer To Employees
📈 PositiveBenzinga•Oct 16, 2025, 08:13 PM•Also: , ,
President Trump Says EMD Serono Will Largely Bring Back Production To The United States; Cost Of Per Cycle Will Fall By 73%; We Will Take Steps To Vastly Expand Coverage Of Fertility; Americans Will Be Able To Opt In To Specialized Coverage For Fertility
📈 PositiveBenzinga•Oct 16, 2025, 07:56 PM•Also: , ,
President Trump Says We Will Dramatically Slash Cost Of IVF; I Am Pleased To Announced EMD Serono Has Agreed To Provide Massive Discounts On Fertility Drugs Sold In The U.S.; EMD Serono Agrees That All Future Drugs Will Be Offset At Most Favored Nation Prices
➖ NeutralBenzinga•Oct 16, 2025, 07:52 PM•Also: , ,
Progyny gains as White House reportedly eyeing proposal to make IVF more accessible
📈 PositiveSeeking Alpha•Oct 16, 2025, 05:49 PM
Shares of fertility stocks are trading higher following a report suggesting that the White House is set to announce a proposal that would make IVF more accessible.
📈 PositiveBenzinga•Oct 16, 2025, 05:02 PM•Also: , ,
Frequently Asked Questions about PGNY
What is PGNY's current stock price?
Progyny, Inc. (PGNY) is currently trading at $26.63 per share. The stock has moved +1.80% today.
What is the analyst price target for PGNY?
The average analyst price target for PGNY is $29.50, based on 1 analyst.
What sector is Progyny, Inc. in?
Progyny, Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NASDAQ exchange.
What is PGNY's market cap?
Progyny, Inc. has a market capitalization of $2.30 billion, making it a mid-cap company.
Does PGNY pay dividends?
No, Progyny, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALVO
Alvotech
$4.90
Mkt Cap: $1.5B
GDRX
GoodRx Holdings, Inc.
$2.77
Mkt Cap: $0.9B
OMCL
Omnicell, Inc.
$46.84
Mkt Cap: $2.2B
OMDA
Omada Health
$14.50
Mkt Cap: $0.8B
PHR
Phreesia, Inc.
$16.55
Mkt Cap: $1.0B
SDGR
Schrödinger, Inc.
$17.66
Mkt Cap: $1.3B
SEM
Select Medical Holdings Corporation
$15.01
Mkt Cap: $1.9B
TDOC
Teladoc Health, Inc.
$7.23
Mkt Cap: $1.3B
TXG
10x Genomics, Inc.
$16.05
Mkt Cap: $2.0B
UFPT
UFP Technologies, Inc.
$229.40
Mkt Cap: $1.8B
Explore stocks similar to PGNY for comparison